There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paragon 28 (FNA – Research Report) and Genmab (GMAB – Research Report) with bullish sentiments.
Paragon 28 (FNA)
In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Paragon 28, with a price target of $23.00. The company’s shares closed last Thursday at $11.12.
According to TipRanks.com, Turkaly is a 1-star analyst with an average return of
Currently, the analyst consensus on Paragon 28 is a Strong Buy with an average price target of $18.00, representing a 51.0% upside. In a report issued on March 28, Needham also reiterated a Buy rating on the stock with a $17.00 price target.
See today’s best-performing stocks on TipRanks >>
Genmab (GMAB)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab today and set a price target of $50.00. The company’s shares closed last Thursday at $30.40.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of
Genmab has an analyst consensus of Moderate Buy, with a price target consensus of $39.58, representing a 30.5% upside. In a report issued on March 26, Truist Financial also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FNA:
